|Home | About | Journals | Submit | Contact Us | Français|
In our previous study, we screened autism spectrum disorder (ASD) patients with and without sleep disorders for mutations in the coding regions of circadian-relevant genes, and detected mutations in several clock genes including NR1D1. Here, we further screened ASD patients for NR1D1 mutations and identified three novel mutations including a de novo heterozygous one c.1499G>A (p.R500H). We then analyzed the role of Nr1d1 in the development of the cerebral cortex in mice. Acute knockdown of mouse Nr1d1 with in utero electroporation caused abnormal positioning of cortical neurons during corticogenesis. This aberrant phenotype was rescued by wild type Nr1d1, but not by the c.1499G>A mutant. Time-lapse imaging revealed characteristic abnormal migration phenotypes in Nr1d1-deficient cortical neurons. When Nr1d1 was knocked down, axon extension and dendritic arbor formation of cortical neurons were also suppressed while proliferation of neuronal progenitors and stem cells at the ventricular zone was not affected. Taken together, Nr1d1 was found to play a pivotal role in corticogenesis via regulation of excitatory neuron migration and synaptic network formation. These results suggest that functional defects in NR1D1 may be related to ASD etiology and pathophysiology.
Autism spectrum disorder (ASD) is a developmental disorder characterized by varying degrees of deficits in social interaction, and restricted and repetitive behaviors1. It is currently estimated that 1.5% of children are diagnosed with ASD2. ASD is associated with problems in the early developmental period and frequently accompanied by comorbid conditions, including hyperactivity, panic, self-injury and sleep disturbance. Among them, sleep disruption, such as insomnia or a short sleep cycle, is one of the most common and distressful problems3,4. A study, based on parental reports, estimated that 44–83% of children with ASD5 have sleep problems, compared with 25–40% of typically developing children6.
The circadian rhythm is a fundamental regulatory factor in cells throughout the bodies of most organisms7. In mammals, the autonomous rhythm of the individual cell is entrained by hormonal and neuronal signals from a central circadian clock located in the suprachiasmatic nuclei of the hypothalamus, and is reset daily by light8. The core circadian clock mechanism is composed of two interlocked transcriptional negative feedback loops9. In the primary loop, transcriptional activators, Bmal1 (Arntl) and Clock (or its ortholog Npas2), form a DNA-binding heterodimer and drive expression of Per1/2/3 and Cry1/2 genes. These protein products ultimately feed back to repress Bmal1-Clock activity. This loop also drives rhythmic expression of the nuclear hormone receptors, Nr1d1 (nuclear receptor subfamily 1 group D member 1, also known as Rev-Erbα) and Nr1d2 (Rev-Erbβ), which in turn rhythmically repress the expression of Bmal1 and Clock as the second loop10,11. Recently, abnormalities of circadian-relevant genes such as PER1, CLOCK, MTNR1A and MTNR1B have been reported to be associated with the pathogenecity of ASD12,13,14. We also recently demonstrated that mutations in NR1D1 and other various circadian-relevant genes possibly affecting their product functions were more frequent in ASD patients than in matching controls15. Thus, circadian-relevant proteins were likely to be involved in brain development, and the impaired molecular clock mechanisms may possibly contribute to the etiology of ASD.
NR1D1 is located on 17q11.2, which was shown to be a ASD susceptibility region16,17 and has been demonstrated to regulate the transcription of target genes18,19. As for neuronal function, while synaptic activity induced the distribution of Nr1d1 to the spine and dendrites in wild-type mice20, Nr1d1-knockout mice displayed abnormal behaviors such as marked hyperactivity, impaired response habituation in novel environments, deficient contextual memories and impairment in nest-building ability21. The above observations raise the possibility that NR1D1 is crucial for synaptic functions and is a causal gene candidate for ASD and other neurodevelopmental disorders.
In the present study, we identified three novel mutations in NR1D1 in ASD patients, and performed in vivo analyses to elucidate the role of Nr1d1 in corticogenesis. While Nr1d1 did not appear to participate in neuronal cell proliferation, its deficiency was shown to impair migration, axon growth and dendritic arbor development of excitatory pyramidal neurons. These results strongly suggest a role of NR1D1 in brain development and its involvement in the etiology of ASD.
By direct sequencing analyses of ASD patients, we detected single base changes with an amino acid substitution in the coding region of NR1D1 in four individuals (Table 1). These mutations were not detected in the Japanese and Caucasian controls. Among the mutations detected, c.1012C>T (p.P338S) and c.1031A>C (p.N344T) were identified as the rare SNPs rs143682026 (A=0.0040/20) and rs145435357 (G=0.0008/4), respectively. Variant effect prediction tools found the c.1012C>T mutation to most likely be non-pathogenic and only one tool suggested c.1031A>C to be disease causing (Table 1). In addition, neither mutation was related to the disease in the pedigree analyses (Fig. 1). On the other hand, we recently reported on a patient with another missense mutation, c.58A>C (p. S20R) (Figs 1A and and2A2A)15, and this mutation was also detected in the father. The patient also presented an additional missense c.2537G>A mutation (p.R846Q) in SHANK2 inherited from her mother which encodes a synaptic scaffold protein. The NR1D1 c.58A>C mutation could impair gene product function by Mutation Tester analysis. The father also carried the mutation c.1673C>T (p.S558L), rs201903415 (A=0.00002/2). This mutation was not detected in the patient, but was detected in 3 out of 121 samples in the Japanese controls. Meanwhile, we identified a novel de novo heterozygous missense mutation, c.1499G>A, causing an arginine to histidine substitution (p.R500H) in one Caucasian sample (Figs 1E and and2B).2B). This mutation was predicted to disrupt NR1D1 protein function by all three pathogenic analyses (Table 1). Interestingly, the c.1499G>A mutation is located in the ligand-binding region of NR1D1 (UniProt; http://www.uniprot.org/uniprot/P20393). Other mutations in NR1D1 were not detected in the families analyzed in this study.
As for clinical symptoms, the patient with the c.1499G>A (p.R500H) mutation (AU1098302) had typical features of ASD. He could not maintain eye contact and appreciate emotions of others. He could speak unilaterally but could not communicate with others. He had repetitive and stereotypical speech, but no ritualistic movements. His memory was very well developed. Despite the mutation in a clock gene, he had no difficulty in sleep induction. Although the patient had an ASD-affected brother, the c.1499G>A mutation was not detected in the brother and his phenotype was a little bit different. The brother had strong anxiety and little sociability without verbal communication with others. Based on the genetic results and clinical features of the patient, we focused on the effects of NR1D1 deficiency on cortical development and analyzed the pathophysiological significance of the c.1499G>A mutation.
From the genetic analyses of the patient, NR1D1 could possibly be a contributing gene for the ASD phenotype. To test this possibility with in vivo analyses, we designed three RNAi vectors, pSUPER-mNR1D1#1, #2, and #3, against distinct regions in the mouse Nr1d1 coding sequence. All the three vectors efficiently knocked down Nr1d1 expression in COS7 cells (Fig. 3A). While pSUPER-mNR1D1#1 and #2 did not affect the expression of the Nr1d1-related molecule, Nr1d2, pSUPER-mNR1D1#3 knocked down Nr1d2 as well (Fig. 3B). We prepared an RNAi-resistant version of Nr1d1, Nr1d1-R, and confirmed its resistance to pSUPER–mNR1D1#1 (Fig. 3C). We used Nr1d1-R in the rescue experiments.
We first examined mRNA expression profiles of Nr1d1 through in situ hybridization during mouse brain development. Nr1d1 showed considerably low expression in the subventricular zone (SVZ)/ventricular zone (VZ) and cortical plate (CP) from E15 to P8 (Fig. 4A–D). It is notable that Nr1d1 appeared to be expressed moderately in layer IV of the somatosensory area at P0 and P8 (Fig. 4C arrowheads and D) when compared to the control experiment (Fig. 4E). At P8, relatively strong expression was detected in the hippocampus (Fig. 4D).
To investigate whether functional defects of Nr1d1 induce abnormal brain development which might be related to etiology of ASD, we performed RNAi experiments in embryonic mouse brains. Effects of Nr1d1-silencing on the migration of newly generated cortical neurons were examined with the in utero electroporation technique. pSUPER-mNR1D1#1 or #3 was electropolated with pCAG-EGFP into progenitor and stem cells in VZ of E14.5 mice brains. When the localization of transfected cells and their progeny was analyzed at P2, control vector-transfected neurons migrated normally to the superficial layer (bin1; layer II-III) of CP (Fig. 5A a and B). In contrast, cells transfected with pSUPER-mNR1D1#1 or #3 frequently remained in the lower part of CP and the intermediate zone (IZ) (Fig. 5A b and c and B). Given that pSUPER-mNR1D1#3 silences both Nr1d1 and Nr1d2 in COS7 cells, statistically similar phenotypes by pSUPER-mNR1D1#1 and #3 might indicate a minor role of Nr1d2 in cortical neuron positioning. Since pSUPER-mNR1D1#1 was specific for Nr1d1, we used this RNAi vector in the subsequent experiments.
Rescue experiments were then conducted to rule out off-target effects. When pCAG-EGFP was electroporated into the VZ cells with pSUPER-mNR1D1#1 together with pCAG-Myc- Nr1d1-R, the positional defects were significantly rescued at P2 (Fig. 5A d and B). It is notable that the patient-related mutant Nr1d1-R500H could not rescue the phenotype under the same conditions (Fig. 5A e and B). Since cell migration is tightly associated with the cell shape, morphology of Nr1d1-deficient neurons was examined in the lower CP. Consequently, the mispositioned cells frequently showed abnormal phenotypes such as multipolar-like morphology and shapes with a branched leading process (Fig. 5C). When cortical neuron migration was examined at a later time point (P7), migration was still prevented and many Nr1d1-deficient neurons failed to reach their target destination (layers II–III) (Fig. 5D).
Taken together, these results strongly suggest that functional defects of Nr1d1 may disrupt cortical neuron migration and cause abnormal cortical architecture. The mutation c.1499G>A might be implicated in pathogenesis and pathophysiology of ASD.
The abnormal positioning of Nr1d1-deficient neurons might be caused by reduced migration velocity. Alternatively, the positional defects may be attributable to the migration into aberrant directions in CP rather than the reduced velocity. We thus performed time-lapse imaging of Nr1d1-deficient cortical neurons migrating in IZ and CP. To this end, VZ progenitor and stem cells were electroporated with pCAG-EGFP together with pSUPER-H1.shLuc (control) or pSUPER-mNR1D1#1 at E14.5, and migration was monitored from E16.5. At the beginning of imaging, Nr1d1-deficient cells showed apparently normal phenotypes in upper IZ and the IZ/CP boundary; they were multipolar and some fraction of them were transforming into the bipolar status like control cells (Fig. 6A). Nr1d1-deficient cells appeared to transform normally from multipolar to bipolar at upper IZ as in the case of the control cells. The initiation of radial migration of the deficient cells was also found to be normal after the multipolar-bipolar transition (Supplementary video 1–4). However, at later time points, abnormal morphological phenotypes frequently came to be observed for the deficient cells migrating in CP (Fig. 6B a–d, Supplementary video 1–4). Notably, some Nr1d1-deficient neurons were observed to jump in a tangential direction, under the conditions where control neurons exhibited steady migration in a radial direction (Fig. 6B a and b, Supplementary video 1 and 2). Nr1d1-deficient cells also sometimes displayed sudden upside-down cell polarity change followed by aberrant migration to the reverse direction (Fig. 6B c, Supplementary video 3). In addition, abnormal morphological change in a complex manner was monitored in some deficient neurons during radial migration (Fig. 6C d, Supplementary video 4). While we observed the abovementioned characteristic migration phenotypes frequently, majority of Nr1d1-deficient neurons displayed apparently normal radial migration profile in CP. Thus, their average migration speed was not statistically different from that of control cells (Fig. 6D). The abnormal morphological phenotypes are likely to be observed when the RNAi effect is relatively strong.
Since neuronal migration delay was observed in the case of a prolonged cell cycle22, we looked into the possible role of Nr1d1 in the cell cycle regulation of neuronal progenitor and stem cells in VZ. When the impact of Nr1d1-knockdown on the cell cycle was examined by labeling S-phase cells with EdU to detect DNA replication, Nr1d1-deficient cells entered S-phase to a similar extent as the control cells and G1-progression rate not statistically differ between control and deficient cells (Fig. 7A and B). Nr1d1-knockdown was therefore suggested to have little effects on the cell proliferation at VZ/SVZ. Furthermore, the positioning of the EdU/EGFP double-positive cells within VZ/SVZ was not affected by the knockdown (Fig. 7A). Collectively, we conclude that Nr1d1-deficiency does not influence the cell cycle in VZ cells, and that abnormal neuron positioning by Nr1d1-knockdown was attributable to cell migration defects.
Given that ASD clinical phenotypes are associated tightly with impaired synapse functions, functional defects of Nr1d1 may disrupt not only cortical neuron migration but also axon elongation during corticogenesis. We thus analyzed interhemispheric axon projections of Nr1d1-deficient neurons. When Nr1d1 was silenced in the VZ cells at E14.5 and axons were observed at P2, axon density of the deficient neurons became lower after crossing the corpus callosum (CC) when compared to control cells (Fig. 8Aa b and B). It is notable that this phenotype was rescued by Nr1d1-R (Fig. 8Ac and B). Since this phenotype could be due to a developmental delay, we tested if axons of the deficient neurons eventually ended up extending correctly. Consequently, axon growth of the deficient neurons was found to be delayed, but not prevented, since axons extended efficiently into the contralateral cortex at P10 (Fig. 8C). Taken together, Nr1d1 is likely required for axon growth of excitatory neurons from the ipsilateral to the contralateral cortex, and disturbance of which might affect synapse network formation.
We next examined the role of Nr1d1 in dendrite development. Introduction of pSUPER-mNR1D1#1 at E14.5 into VZ cells resulted in highly abrogated dendritic arborization at P7 when compared to the control phenotype (Fig. 9A a and b). Both branch point number and total length of dendrites were lower in the deficient neurons than the matching control cells (Fig. 9B and C). It should be noted that these aberrant phenotypes were rescued by Nr1d1-R (Fig. 9Ac,B and C). Collectively, the obtained data suggest that Nr1d1 plays a crucial role in dendrite growth and maintenance, and that the functional loss of Nr1d1 impairs neuronal connectivity through disturbance of dendrite growth as well as axon elongation. Since the development of the neuronal network is essential for brain function, the clinical features of ASD with NR1D1 gene abnormalities may reflect the observed cellular phenotypes.
While sleep is thought to be essential for synaptic development and brain maturation23, possible interplay of synaptic and clock genes has been proposed in ASD pathogenecity24. We have detected mutations in various circadian-related genes, including NR1D1 by the screening of ASD patients (Fig. 1)15. Further screening of ASD patients for NR1D1 mutations revealed novel mutations, including c.1499G>A (p.R500H), which was predicted to have deleterious effects on gene function based on pathogenic prediction analyses in silico. Although the younger brother of the patient was also diagnosed as autistic, no mutation was found in the NR1D1 gene, suggestive of an abnormality in as yet an unidentified gene(s) when considering numerous causal gene candidates for ASD25,26. Alternatively, there may also exist a recessive inheritance of a yet unidentified gene in the pathogenesis of the present patient. In such a case, NR1D1 may be one of many polygenic factors. Further genetic study with a much larger sample size is required to elucidate the pathogenic significance of NR1D1 gene abnormalities.
We examined the possible contribution of NR1D1 to neuronal development, based on the prediction that the c.1499G>A mutation is pathogenic for this patient as it was located in the ligand-binding region in NR1D1. Since ligand-binding is thought to cause a conformational change in NR1D1 that induces a response and acts as a molecular switch to turn the transcriptional activity on, the c.1499G>A mutation may impair the physiological role of NR1D1 and consequently contribute to the pathogenesis of the patient. In this regard, the mutation was predicted to be “probably damaging” (score 0.946) by PolyPhen-2, “deleterious” (score 0.01) by SIFT and “disease causing” (score 29) by Mutation Transfer analyses.
NR1D1 is known to negatively regulate the expression of circadian clock proteins as mentioned earlier. Meanwhile, Nr1d1 has been reported to participate in neuronal architecture and function during the brain development, through the interaction with Oligophrenin-1, a GTPase-activating protein for Rho small GTPases20. Oligophrenin-1 has been demonstrated to regulate dendritic spine morphology27, and its gene abnormalities are considered to cause intellectual disability (ID) and cerebellar hypoplasia28. Oligophrenin-1 is likely to recruit Nr1d1 to dendrites, reduce its repressor activity and protect Nr1d1 from degradation20. Interestingly, while Oligophrenin-1 appears to be involved in the circadian cycle through the expression of clock genes, including Nr1d1, synaptic activity may reciprocally regulate the Nr1d1 accumulation to dendrites and spines20. Collectively, functional defects of NR1D1 as well as Oligophrenin-1 are likely to relate to the pathophysiology of neurodevelopmental disorders such as ASD and ID.
Unlike wild type Nr1d1, Nr1d1-R500H could not rescue the migration defects in the knockdown experiments, indicating that functional impairment of Nr1d1 presumably takes part in the etiology of the present ASD case. It is not clear whether c.1499G>A mutation serves as a loss-of-function mutation or dominant negative one. In the latter case, the interaction of the remaining normal NR1D1 with its physiological binding partners might be prevented by NR1D1-R500H under haploinsufficiency conditions. In either case, partial but not complete inhibition of NR1D1 activity may contribute to the abnormal phenotypes observed in this study. In addition to the neuronal migration defects, interhemispheric axon projection and dendritic arbor formation were abrogated when Nr1d1 was silenced in the developing mouse cerebral cortex. Since Nr1d1 is a component of a transcription machinery, inhibition of its function may cause a variety of functional defects in neuronal cells. It remains to be determined if the defects in neuronal network function and/or maintenance really occur in individuals with defective NR1D1 function, and, if they do, how the abnormality determines the clinical features.
Based on the observation in this study, NR1D1 is likely to contribute to cortical development through regulation of neuronal migration and synaptic network formation. The present study suggests that functional defects of NR1D1 may be implicated in the etiology and pathophysiology of ASD and other neurodevelopmental disorders, although further genetic and cell biological analyses are required to fully address the issue.
The clinical study was approved by the bioethics committee for human gene analysis at Jichi Medical University (approval number 11–14) in accordance with the principles of the Declaration of Helsinki, and the Ethical Guidelines for Human Genome/Gene Analysis Research by the Ministry of Education, Culture, Science, and Technology, the Ministry of Health, Labor, and Welfare, and the Ministry of Economy, Trade, and Industry of Japan. Written informed consent was obtained from the parents of the patients. We followed the fundamental guidelines for proper conduct of animal experiments and related activity in academic research institution under the jurisdiction of the Ministry of Education, Culture, Sports, Science and Technology, Japan. All the protocols for animal handling and treatment were reviewed and approved by the animal care and use committee of Institute for Developmental Research, Aichi Human Service Center (approval number M-10).
We screened Japanese and Caucasian samples of ASD patients for NR1D1 gene mutation. The patients were diagnosed as autism, Asperger syndrome, pervasive developmental disorder based on the DSM-IV criteria, or ASD based on the DSM-V criteria. DNA samples of 111 Caucasian patients with ASD were obtained from the Autism Genetic Resource Exchange (AGRE) Consortium (Cure Autism Now, Los Angeles, CA). Caucasian control samples from 158 typically developing children were obtained from the Coriell Institute (Camden, NJ). DNA samples from 87 Japanese patients with ASD and 133 Japanese control samples were obtained from the sample stock at the Department of Pediatrics, Jichi Medical University. The intelligence quotient and language ability of the ASD patients varied from severely affected to normal. All lymphocyte samples were obtained from patients with informed consent from themselves or their parents. Lymphocytes were transfected with Epstein-Barr virus to establish lymphoblasts and cultured. Genomic DNA was then extracted using salting-out methods15.
Exons in which mutations were detected were verified by Sanger sequencing analyses. PCR was performed to amplify each exon containing a mutation and its neighboring introns. PCR products were analyzed using the 3730xl DNA Analyzer (Applied Biosystems, Foster City, CA). The primer sequence information will be provided on request.
The sequencing results were aligned to genomic reference sequences and called variants were compared with the reference genome using the 454 integrated software (GS Reference Mapper, Roche). We searched for mutations in the exons of NR1D1. A sample was considered mutated if a mutation was present in a minimum of approximately 50% of the confident reads. Genomic reference sequences were ascertained by the NCBI website (http://www.ncbi.nlm.nih.gov/gene/). Each coding polymorphism was compared to the dbSNP (http://www.ncbi.nlm.nih.gov/snp/) and the corresponding reference (rs) number was assigned to previously identified polymorphisms. Japanese mutations were also ascertained by the human database website (http://biosciencedbc.jp/en/) of the National Bioscience Database Center of the Japan Science and Technology Agency. The patients, their siblings and parents were tested for mutations in all exons of NR1D1. The hypothesized effects of the mutations on respective protein functions were analyzed using prediction tools PolyPhen-2 (http://genetics.bwh.harvard.edu/pph2/), SIFT (http://sift.jcvi.org/) and Mutation Taster (http://www.mutationtaster.org/).
Mouse Nr1d1 and Nr1d2 cDNAs were obtained from Dr. T. Takumi (RIKEN, Saitama, Japan) and constructed into pCAG-Myc vector (Addgene Inc., Cambridge, MA). pCAG-histone 2B (H2B)-EGFP was used to label chromosomes29. pCAG-M-Cre was kindly supplied by Dr. S. Miyagawa (Univ. Osaka, Japan)30. pCALNL(loxP-neomycin-loxP)-RFP was made as previously described29. For RNAi experiments, pSUPER-RNAi-puro vector (OligoEngine, Seattle, WA) was designed to target three distinct coding sequences in mouse Nr1d1 cDNA (pSUPER-mNR1D1#1, 5′-GGACCAGACAGTGATGTTC-3′, 1477–1495; pSUPER-mNR1D1#2, 5′-GGCAACACCAAGAATGTTC-3′, 1229–1447; pSUPER-mNR1D1#3, 5′-GTAGAGTTTGCCAAACACA-3′, 1354–1372). Numbers indicate the position from the transcription start site. We used pSUPER-H1.shLuc designed against luciferase as a control RNAi vector29. To generate an RNAi-resistant Nr1d1, Nr1d1-R, silent mutations were introduced, as underlined, in the target sequence (5′- GGATCAAACGGTCATGTTC -3′, 1477–1495). The Nr1d1 mutant, Nr1d1-R500H, was prepared using KOD-Plus Mutagenesis kit (Toyobo, Osaka, Japan) with Nr1d1-R as a template. All constructs were verified by DNA sequencing.
Coronal sections of mouse brain at embryonic day (E)14, E16 and postnatal (P)0 were probed using a digoxigenin-labeled antisense riboprobe directed against full length mouse Nr1d1 cDNA as previously described31. The sense riboprobe was used for the control experiment.
COS7 cells were transfected with Lipofectamine 2000 (Life Technologies Japan, Tokyo). SDS-PAGE and western blotting were performed as previously described34. Immunofluorescence analyses were carried out as previously described35. Alexa Fluor 488- or 568-labeled IgG (Life Technologies Japan) was used as a secondary antibody. Fluorescent images were captured with FV-1000 confocal laser microscope (Olympus, Tokyo, Japan).
In utero electroporation was carried out essentially as previously described36,37 at E14.5. At least 5 brains were used for each experiment. Live-imaging analyses were conducted as described previously31.
Three electroporated brains from different dams were used for each experiment. Distribution of GFP-positive neurons in brain slices was quantified as follows. The coronal sections of cortices containing the labeled cells were classified into 5 bins and IZ as previously described29,38. The number of labeled cells (more than 100 per sample) of at least 5 slices per brain was calculated. For estimation of axon growth, GFP signal intensity of callosal axons was measured in the marked areas on the ipsilateral (before entering the CC) and contralateral (after leaving the CC) sides. We then calculated the ratio of the contralateral signal intensity to that in the corresponding ipsilateral side using ImageJ software.
Cell cycle analysis was performed essentially as previously described31. Embryos were electroporated in utero with pCAG-H2B-EGFP together with pSUPER-H1.shLuc (control) or pSUPER-mNR1D1#1 at E14.5. GFP and EdU were detected with anti-GFP and Alexa Fluor555 azide (Life Technologies Japan), respectively. The number of cells used for each calculation was more than 100.
Results were expressed as means±SD. When data were obtained from only 2 groups, Student’s t-test was used for comparison. For other experiments, the rate of cell scores was initially analyzed using the one-way analysis of variance (ANOVA). Subsequently, Fisher’s least significant difference test (LSD) was applied to absolute values as a post hoc test of multiple comparisons. The level of statistical significance was considered to be p<0.05. Statistical analysis was performed using Statview software (SAS Institute, Cary, NC).
How to cite this article: Goto, M. et al. Role of a circadian-relevant gene NR1D1 in brain development: possible involvement in the pathophysiology of autism spectrum disorders. Sci. Rep. 7, 43945; doi: 10.1038/srep43945 (2017).
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
We thank Mr. Keith A. Boroevich (RIKEN Center for Integrative Medical Sciences, Japan) for critical reading of the manuscript. This work was supported in part by JSPS KAKENHI Grant (grant number 24390271, 23390275, and 26893252), MEXT-Supported Program for the Strategic Research Foundation at Private Universities 2011–2015 (Cooperative Basic and Clinical Research on Circadian Medicine), and by a grant-in-aid of the Practical Research Project for Rare/Intractable Diseases from Japan Agency for Medical Research and Development (AMED) (grant number 15ek0109040h0002).
The authors declare no competing financial interests.
Author Contributions M.G. evaluated the patient and obtained clinical information, participated in genetic analyses and drafted the manuscript. M.M. performed mouse in utero electroporation and immunohistochemical analyses. HT carried out in situ hybridization, and provided guidance for in utero electroporation and performed time-lapse imaging analyses. A.M., and Z.Y. participated in genetic analyses. E.F.J. helped with the interpretation of the data in genetic analyses. K.N. designed and made RNAi- and expression-vectors, and carried out biochemical analyses. T.Y and K.N. conceived and designed the experiment, and helped to draft the manuscript. All authors read and approved the final manuscript.